Morice, A., et al. (2025). FGFR antagonists restore defective mandibular bone repair in a mouse model of osteochondrodysplasia. Bone Research. doi.org/10.1038/s41413-024-00385-x.

The study calls for further clinical trials to test FGFR and NOTCH inhibitors in ETMR patients and explores antisense therapies targeting C19MC miRNAs, which have shown promise in lab settings.

A new study explores the potential of fibroblast growth factor receptor (FGFR) antagonists in restoring defective mandibular bone repair in mouse models of osteochondrodysplasia, a group of ...

Coming into the FGFR amplification. So, this is another promising target. It is definitely a newer target. The FGFR signaling pathways are implicated in tumor growth and survival.

Unfortunately, a first clinical study showed that the mere presence of amplification as a selection criterion for personalized FGFR therapy in patients is not yet sufficient.

In their review, the authors describe the FGFR pathway, its role in oncogenesis, current FGFR inhibitors, the role these inhibitors play in treatment cholangiocarcinoma, and the future of the field.

Background: Fibroblast growth factor receptor (FGFR) gene fusions and rearrangements are involved in the pathogenesis of approximately 10 to 16 percent of patients with cholangiocarcinoma. There is no ...

T. Helsten, S. Elkin, E. Arthur et al. The FGFR landscape in cancer: Analysis of 4,853 tumors by next-generation sequencing. Clinical Cancer Research 2016 (22), 259-267 ...

Please provide your email address to receive an email when new articles are posted on . Median OS favored patients treated with erdafitinib over chemotherapy (12.1 months vs. 7.8 months). Patients ...

Gain-of-function mutations in fibroblast growth factor receptor (FGFR) genes are known to cause a range of skeletal disorders, such as craniosynostosis and chondrodysplasia, which severely affect ...